Biogen Inc. Common Stock (BIIB) Financials
Key financial figures for Biogen Inc. Common Stock (Q2 2026).
Biogen posted Q2 2026 total revenue of $2.74 billion (+3% YoY), but GAAP diluted EPS fell to $0.66 from $4.33 a year ago on lower operating income, while non-GAAP diluted EPS held roughly flat at $3.60. Total revenue of $2.74 billion, up 3% year-over-year, driven by the growth portfolio and recently acquired products. GAAP diluted EPS dropped to $0.66 (vs $4.33 in Q2 2025); non-GAAP diluted EPS was $3.60 (vs $5.47 in Q2 2025). LEQEMBI Alzheimer's collaboration revenue grew to $63.7 million from $54.9 million a year ago, continuing its ramp. ZURZUVAE revenue rose 53% year-over-year to $70.8 million; SKYCLARYS continued growing to $167.9 million. SPINRAZA ($401.9M) and TYSABRI ($450.8M) were roughly flat year-over-year; VUMERITY declined to $196.5 million from $212.3 million. Figures are for Q2 2026, as Biogen Inc. reported them.
- Revenue
- $2.7B
- Net Income
- $98M
- EPS
- $0.66
- Total Assets
- $32.1B
- Operating Cash Flow
- $449M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $2.7B | $98M | $0.66 | 11.63% | |
| Q1 FY2026 | $2.5B | $320M | $2.15 | 16.04% | |
| Q4 FY2025 | $2.3B | -$48M | -$0.33 | -2.5% | |
| Q3 FY2025 | $2.5B | $467M | $3.17 | 25% | $1.2B |
| Q2 FY2025 | $2.6B | $635M | $4.35 | 22.23% | $144M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $9.8B | $1.3B | $8.83 | 19.14% | $2.1B |
| FY2024 | $9.7B | $1.6B | $11.19 | 25.74% | $2.5B |
| FY2023 | $9.8B | $1.2B | $7.97 | 21.32% | $1.2B |
Frequently asked questions
What was Biogen Inc.'s revenue last quarter?
Biogen Inc. reported revenue of $2.74 billion for Q2 FY2026, up 3.4% from the same period a year earlier.
Is Biogen Inc. profitable?
Yes. Biogen Inc. reported net income of $97.5 million for Q2 FY2026, a net margin of 3.56% on revenue.
How has Biogen Inc.'s margin trended?
Operating margin was 11.63% in Q2 FY2026, compared with 22.23% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How many quarters of Biogen Inc. financials does SentiSense hold?
SentiSense holds up to forty quarters and twenty fiscal years of income statement, balance sheet and cash flow history for BIIB. The 5 most recent quarters are summarised above.
Full income statement, balance sheet and cash flow for Biogen Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.